NCT03574792View on ClinicalTrials.gov

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

NACompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

April 19, 2021

Study Completion Date

November 11, 2021

Conditions
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
DRUG

Gabapentin

Given PO

DRUG

Methadone

Given PO

DRUG

Oxycodone

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Venlafaxine

Given PO

DRUG

Venlafaxine Hydrochloride Extended Release

Given PO

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT03574792 - Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy | Biotech Hunter | Biotech Hunter